| HNRNPA1 — Heterogeneous Nuclear Ribonucleoprotein A1 | |
|---|---|
| Symbol | HNRNPA1 |
| Full Name | Heterogeneous Nuclear Ribonucleoprotein A1 |
| Chromosome | 12q13.13 |
| NCBI Gene | 3178 |
| Ensembl | ENSG00000166086 |
| OMIM | 164017 |
| UniProt | P09651 |
| Diseases | Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Inclusion Body Myopathy |
| Expression | Ubiquitous, high in brain and muscle |
Hnrnpa1 Heterogeneous Nuclear Ribonucleoprotein A1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
HNRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1) is a gene located on chromosome 12q13.13 that encodes an abundant RNA-binding protein with critical roles in RNA processing, splicing, and transport 1. The gene is catalogued as NCBI Gene ID 3178 and OMIM 164017. HNRNPA1 is a member of the heterogeneous ribonucleoprotein (hnRNP) family, which are nuclear proteins that bind pre-mRNA and regulate various aspects of RNA metabolism.
HNRNPA1 is ubiquitously expressed with high levels in the brain and muscle. The protein contains two RNA recognition motifs (RRMs) and a prion-like domain that enables liquid-liquid phase separation (LLPS) and stress granule formation. Pathogenic mutations in HNRNPA1 cause amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and inclusion body myopathy, linking RNA metabolism dysregulation to neurodegenerative disease 2.
HNRNPA1 contains several functional domains:
RNA Recognition Motif 1 (RRM1): The N-terminal RRM (aa 106-184) binds to RNA sequences with the consensus motif UAG. This domain has the highest RNA-binding affinity.
RNA Recognition Motif 2 (RRM2): The C-terminal RRM (aa 191-267) provides additional RNA binding and protein-protein interactions.
Glycine-Rich Domain: A glycine-rich region (aa 1-105) that mediates protein-protein interactions and contains the nuclear localization signal (NLS).
Prion-like Domain (PrD): The C-terminal region (aa 320-370) is enriched in glycine, glutamine, asparagine, and tyrosine residues. This domain drives liquid-liquid phase separation and stress granule formation through low-complexity sequence interactions 3.
HNRNPA1 is a key splicing regulator that:
Key splicing events regulated by HNRNPA1 include:
HNRNPA1 participates in RNA transport to dendritic and axonal compartments:
One of the key pathogenic mechanisms involves dysregulated stress granule biology:
Stress Granule Formation: Under cellular stress (oxidative, heat, osmotic), HNRNPA1 translocates to stress granules—membrane-less organelles that transiently store翻译 stalled mRNPs.
LLPS Dysregulation: The prion-like domain mediates phase separation. Mutations alter this property, leading to:
Sequestration of TDP-43: HNRNPA1 inclusions sequester TDP-43, disrupting its nuclear function and promoting TDP-43 pathology—a hallmark of ALS/FTD.
Mutant HNRNPA1 causes widespread RNA processing defects:
HNRNPA1 mutations promote formation of:
HNRNPA1 mutations cause familial ALS through dominant toxic gain-of-function mechanisms:
ALS-associated phenotypes:
HNRNPA1 mutations also cause FTD, often with overlapping ALS features:
Mutations cause autosomal dominant inclusion body myopathy:
HNRNPA1 is one of several genes (including HNRNPA2B1, VCP, SQSTM1) causing multisystem proteinopathy, a syndrome featuring:
The study of Hnrnpa1 Heterogeneous Nuclear Ribonucleoprotein A1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.